Vaccines and autism

Laboratory Medicine

Volumn 33, Issue 9, 2002, Pages 708-717

  Rimland, Bernard ^a   McGinnis, Woody ^a  

^a Autism Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B VACCINE; NEOPTERIN; RHESUS D ANTIBODY; THIOMERSAL; VACCINE;

AUTISM; AUTOIMMUNITY; B LYMPHOCYTE; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE MARKER; DRUG SAFETY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; MEASLES; NATURAL KILLER CELL; NEUROTOXICITY; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B;

EID: 0036711056     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1093/labmed/33.9.708     Document Type: Review

References (103)

1. York LJ, Warren RP, Burger RA, et al. CD4+ helper T cell depression in autism. Immunol Lett 1990;25:341-346.
2. Warren RP, Foster A, Margaretten C, et al. Immune abnormalities in patients with autism. J Autism Develop Dis 1986;16:189-197.
3. Warren RP, Yonk LJ, Burger RA, et al. Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol Invest. 1990;19:245-251.
4. Gupta S, Aggarwal S. Heads C. Dysregulated immune system in children with autism: Beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Devel Dis. 1996;26:439-452.
5. Stubbs EG, Crawford ML. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr. 1977;7:49-55.
6. Warren RP, Odell JD, Warren WL, et al. Immunoglobulin A deficiency in a subset of autistic subjects. J Autism Develop Dis. 1997;27:187-192.
7. Fiumara A, Sciotto A, Barone R. Peripheral lymphocyte subsets and other immune aspects in Rett syndrome. Pediatr Neurol. 1999;21:619-621.
8. Warren RP, Foster A, Margaretten NC. Reduced natural killer cell activity in autism. J Am Acad Chld Adolesc Psych. 1987;26:333-335.
9. Warren RP, Singh VK, Cole P. Increased frequency of the null allele at the complement C4b locus in autism. Clin Exp Immunol. 1991;83:438-440.
10. Stubbs EG. Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination. J Autism and Child Schizophr. 1976;6:269-274.
11. Stubbs EG Interferonemia and autism. J Autism Develop Dis. 1995;25:71-73.
12. Croonenberghs J, Bosmans E, Deboutte D, et al. Activation of the inflammatory response system in autism. Neuropsychobiology. 2002;45:1-6.
13. Singh VK. Plasma increase of interleukin-12 and interferon-gamma: Pathological significance in autism. J Neuroimmunol. 1996;66:143-145.
14. Messahel S, Pheasant AE, Pall H, et al. Urinary levels of neopterin and biopterin in autism. Neurosci Lett. 1998;241:17-20.
15. Singh VJ, Warren RP, Odell JD, et al. Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopath. 1991;61:448-455.
16. Peakman M, Verani D. Basic and Clinical Immunology. New York, NY: Churchill Livingston; 1997:108.
17. Comi AM, Zimmerman AW, Frye VH, et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999;14:388-394.
18. Kono DH, Park MS, Szydlik A, et al. Resistance to xenobiotic-induced autoimmunity maps to chromosome 1. J Immunol. 2001;167:2396-2403.
19. Daniels WP, Warren RP, Odell JD, et al. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiol. 1995;32:120-123.
20. Singh VK, Warren RP, Odell JD, et al. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun. 1993;7:97-103.
21. Singh VK, Lin SX, Yang VC. Serological association of measles virus and human herpes virus-6 with brain autoantibodies in autism. Clin Immunol Immunopathol. 1998;89:105-108.
22. Singh VK, Warren R, Averett R, et al. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol. 1997;17:88-90.
23. Connolly AM, Chez MG, Pestronk A, et al. Serum autoantibodies to brain in Laundau-Kleffner variant, autism, and other neurological disorders. J Peds. 1999;134:607-613.]
24. Weizman A, Weizman R, Szekely GA, et al. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiat. 1982;139:1462-1465.
25. Kono DW, Balomenos D, Pearson DL, et al. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-Gamma and not Th1/Th2 imbalance. J Immunol. 1998;161:234-240.
26. Torrente F, Ashwood P. Day R, et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Molec Psych. 2002;7:375-382.
27. El-Fawal H, Waterman SJ, De Feo A, et al. Neuroimmunotoxicology: Humoral assessment of neurotoxicity and autoimmune mechanisms. Environ Hlth Persp. 1999;107:767-775.
28. Chang KW ed. Toxicology of Metals. Boca Raton, FL: CRC Press; 1996:842-845.
29. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001;108:1097-1104.
30. Fagan DG, Pritchard JS, Clarkson TW, et al. Organ mercury levels in infants with omphaloceles treated with organic mercurial antiseptic. Arch Dis Child. 1977;52:962-964.
31. Rohyans J, Walson PD, Wood GA. Mercury toxicity following merthiolate ear irrigations. J Pediatr. 1984;104:311-313.
32. National Academy of Sciences press release, July 21, 2000.
33. van der Laan JW, de Waal E. Safety Working Party Assessment of the Toxicity of Thimerosal in Relation to its Use in Medicinal Products. The European Agency for the Evaluation of Medicinal Products; London: 8 September 1998: B04210.
34. Stratton K, Gable A, McCormick MC, eds. Immunization safety review: Thimerosal-containing vaccines and neurodevelopmental disorders. Immunization safety review committee, board on health promotion and disease prevention, the Institute of Medicine. 2001 Available at: www.iom.edu/imsafety. Accessed on August 7, 2002.
35. TEST Foundation. Available at: www.altcorp.com/testfoundation.htm Accessed on August 7. 2002.
36. Bernard S, Enayati A, Binstock T, et al. Autism: A Unique Type of Mercury Poisoning. Cranford, NJ: ARC Research; 2000: 1-76. Available at: www.autism.com/ari/mercurylong.html. Accessed August 7, 2002.
37. SafeMinds Website Available at: www.dmcreative.tmp.com/safeminds/board.htm. Accessed June 24, 2002.
38. McGinnis WR. Mercury and autistic gut disease. Environ Hlth Persp. 2001;109:303-304.
39. Chen W, Body RL, Mottet NK. Biochemical and morphological studies of monkeys chronically exposed to methylmercury. J Toxicol Environ Hlth. 1983;12:407-416.
40. Horvath K, Papadimitriou JC, Rabsztyn A, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135:559-563.
41. Stejskal VD, Forsback M, Nilsson R. Lymphocyte transformation test for diagnosis of isothiazoline allergy in man. J Invest Derm. 1990;94:798-802.
42. Stejskal VD, Cederbrandt K, Lindvall A, et al. MELISA-an in vitro tool for the study of metal allergy. Toxicol in Vitro. 1994;8:991-1000.
43. Stejskal VD, Forsbeck M, Cederbrant KE. Mercury-specific lymphocytes: An indication of mercury allergy in man. J Clin Immunol. 1996;16:31-40.
44. Tibbling L, Thuomas KA, Lenkei R, et al. Immunological and brain MRI changes in patients with suspected metal intoxication. Int J Occupat Med Toxicol. 1995;4.
45. Stejskal VD, Danersund A, Lindvall A, et al. Metal-specific lymphocytes: Risk factors in CFS and other related diseases. Neuroendocrinol Lett. 1999;20:289-298.
46. Stejskal VD. Human hapten-specific lymphocytes: Biomarkers of allergy in man. Drug Info J. 1997;31:1379-1382.
47. Pang PK, Shan JJ, Lewanczuk RZ, et al. Parathyroid hypertensive factor and intracellular calcium regulation. J Hypertens. 1996;14:1053-1060.
48. Lewanczuk RZ, Benishin CG, Shan J, et al. Clinical aspects of parathyroid hypertensive factor. J Cardiovasc Pharmacol. 1994;23:23-26
49. Tessier-Lavigne M, Mobbs P, Attwell D. Lead and mercury toxicity and the rod light response. Invest Opthalmol Vis Sci. 1985;26:1117-1123.
50. Ritvo ER, Creel D, Realmuto G, et al. Electroretinograms in autism: A pilot study of b-wave amplitudes. Am J Psychiat. 1988:145:1085-1086.
51. Verstraeten T, David R, Destefano F. Risk of neurological and renal impairment associated with thimerosal-containing vaccines. Report to the Advisory Committee on Immunization Practices; Atlanta GA: June 21, 2000.
52. Finegan J, Quarrington B. Pre-, peri-, and neonatal factors and infantile autism. J Child Psych Psychiatr. 1979;20:119-128.
53. Stejskal J. Measles lymphadenopathy. Ultrastruct Pathol. 1980;1:243-247.
54. Dankova E, Kasal P, Bergmannova V, et al. Immunological findings in children with abnormal reactions after immunization. Cesk Pediat. 1993;48:9-12.
55. Wakefield AJ, Murch SH, Linnell J, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637-641.
56. Wakefield AJ, Anthony M, Murch SH, et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol. 2000;95:2285-2295.
57. Walker-Smith J. Letter: Autism, bowel inflammation, and measles. Lancet. 2002;359:705-706.
58. Furlano RI, Anthony A, Day R, et al. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138:366-372.
59. Kawashima H, Mori T, Kashiwagi Y, et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Digest Dis Sci. 2000;45:723-729.
60. Uhlmann V. Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. J Clin Pathol Mol Pathol. 2002;55:1-6.
61. Singh VK. Abnormal measles serology and autoimmunity in autistic children. J Allergy Clin Immunol. 2002;109:S232.
62. Fujinami RS, Oldstone MB, Wroblewska Z, et al. Molecular mimicry in virus infection: Crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Nat Acad Sci USA. 1983;80:2346-2350.
63. Warren RP, Odell JD, Warren WL, et al. Strong association of the third hypervariable region of HLA-DR Beta- I with autism. J Neuroimmunol. 1996;67:97-102.
64. Plioplys AV, Greaves A, Kazemi K, et al. Lymphocyte function in autism and Rett's syndrome. Neuropsychobiol. 1994;7:12-16.
65. Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infec Dis. 1999;29:855-861.
66. Belgamwar RB, Prasad S, Appaya P. Measles, mumps, rubella vaccine induced subacute sclerosing panencephalitis. J Indian Med Assoc. 1997;95:594.
67. Physician's Desk Reference 2002. Montvale NJ: Medical Economics Company; 2002:2120.
68. Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis-clinical and immunologic studies. N Engl J Med. 1984;310:137-141.
69. Caballero B, Rice A. Low serum retinol is associated with increased severity of measles in New York City children. Nutr Rev. 1992;50:191-192.
70. Yalcin SS, Yurdakok K, Ozalp I, et al. The effect of live measles vaccines on serum vitamin A levels in healthy children. Acta Paediatr Jpn. 1998;40:345-349.
71. Butler JC, Havens PL, Sowell AL, et al. Measles severity and serum retinol (vitamin A) concentration among children in the United States. Pediatrics. 1993;91:1176-1181.
72. Gupta PC, Dutta AK, Khare S, et al. Immunoglobulins profile of measles. Indian Pediatr. 1989;26:780-784.
73. Audhya T. Abnormalities and Dysfunction of Vitamins and Fatty Acids in Autism. Defeat Autism Now Symposium, Phoenix, AZ, July 2000.
74. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypoth. 2000;54:979-983.
75. Bhaskaram P. Immunobiology of mild micronutrient deficiencies. Br J Nutr. 2001;85:S75-S80.
76. Richer JM, Cross RG. Gaze aversion in autistic and normal children. Acta Psychiatr Scand. 1976;53:193-210.
77. Schuil J, van de Putte EM, Zwaan CM, et al. Retinopathy following measles, mumps, and rubella vaccination in an immuno-incompetent girl. Int Opthalmol. 1998;22:345-347.
78. Fan PC, Teug RJ, Chou CC, et al. Impaired immune function in a premature infant with zinc deficiency after total parenteral nutrition. Chung Hua Min Kwo Hsiao Erh Kol Hsueh HUI Tsa Chih. 1996;37:64-69.
79. Sazawal S, Jalla S, Mazumder S, et al. Effect of zinc supplementation on cell-mediated immunity and lymphocyte subsets in preschool children. Indian Pediatr. 1997;34:589-597.
80. Folwaczny C. Zinc and diarrhea in infants. J Trace Elem Med Biol. 1997;11:116-122.
81. Walker-Smith JA, Andrews J. Alpha-antitrypsin, autism and celiac disease. Lancet. 1972;2:883-884.
82. Goodwin MS, Cowen MA, Goodwin TC. Malabsorption and cerebral dysfunction: A multivariate and comparative study of autistic children. J Autism Child Schizophr. 1971;1:48-62.
83. Horvath K, Tildon J. The role of secretin in autistic spectrum disorder. Int Rev Research Mental Retard, 2001;23:33-54.
84. D'Eufemia P, Celli M, Finocchiaro R, et al. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996;85:1076-1079.
85. Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogues of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem. 1995;41:1094-1104.
86. Reichelt KL. Biochemistry and psychophysiology of autistic syndromes. Tidsskr Nor Laegeforen. 1994;114:1432-1434.
87. Shattock P. Kennedy A, Rowell F, et al. Role of neuropeptides in autism and their relationships with classical neurotransmitters. Brain Dysfunction. 1991;3:328-325.
88. Knivsberg AM, Reichelt KL, Nodland M. Reports on dietary intervention in autistic disorders. Nutr Neurosci. 2001;4:25-37.
89. Zioudrou C, Streaty RA, Klee WA. Opioid peptides derived from food proteins. The exorphins. J Biol Chem. 1979;254:2446-2449.
90. Fukudome S, Yoshikawa M. Gluten exorphin c. A novel opioid peptide derived from wheat gluten. FEBS Lett. 1993;316:17-19.
91. Chabance B, Marteau P, Rambaud JC. Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochime. 1998;80:155-165.
92. Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res. 1987;412:68-72.
93. Hauser KF. McLaughlin PJ, Zagon IS. Endogenous opioid systems and the regulation of dendritic growth and spine formation. J Comp Neurol. 1989;281:13-22.
94. Barrett AJ, ed. Handbook of Proteolytic Enzymes. Academic Press; 1998:379-382.
95. Srikantaiah MV. Radhakrishnan AN. Studies on the metabolism of vitamin B6 in the small intestine: Part III-purification and properties of monkey intestinal pyridoxal kinase. Indian J Biochem. 1970;7:151-156.
96. Rimland B. High dose vitamin B6 and magnesium in treating autism: Response to study by Findling et al. J Autism Dev Disord. 1998;28:581-582.
97. Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 1995:1725-1768.
98. Stubbs G, Litt M, Lis E, et al. Adenosine deaminase activity decreased in autism. J Amer Acad Chld Psychiatr. 1982;21:71-74.
99. Pangborn JB, Baker SM. Biomedical Assessment Options for Children with Autism and Related Problems. San Diego, CA: Autism Research Institute; 2001:54.
100. Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastroinstest Dis. 1997;8:22-32.
101. Washington K, Stenzel TT, Buckley RH, et al. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol. 1996; 20(10):1240-1252.
102. Ojuawo A, Milla PJ, Lindley KJ. Non infective colitis in infancy: Evidence in favor of minor immunodeficiency in its pathogenesis. East Afr Med J. 1997;74:233-236.
103. Klein N, Jack D. Immunodeficiency and the gut: Clues to the role of the immune system in gastrointestinal disease. Ital J Gastroenterol Hepatol. 1999;31:802-806.